Trial Profile

A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 24 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trametinib (Primary) ; Uprosertib (Primary)
Indications Advanced breast cancer; Triple negative breast cancer
Focus Therapeutic Use

Most Recent Events

01 Feb 2025 Results (n=37) Trametinib monotherapy demonstrating limited efficacy and addition of Uprosertib associated with numerically greater objective responses but no difference in PFS were published in the Breast Cancer Research and Treatment
27 Aug 2019 Status changed from active, no longer recruiting to completed.
03 Mar 2017 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com